Abstract:Abstract Background: Long-term survivors of childhood cancer experience high rates of patient-reported symptoms and evidence for accelerated molecular aging. Both are established to increase the risk for late-mortality (>5 years from cancer diagnosis). We aim to investigate if accelerated molecular aging mediates the association between symptoms and all-cause late-mortality. Methods: DNA methylation (DNAm)-based aging biomarkers were derived from the DNAm Age Calculator, including epigenetic age acceleration (EAA) using multiple clocks (e.g., GrimAge and PhenoAge) and other DNAm-predicted biomarkers (e.g., DNAmB2M: beta-2-microglobulin, DNAmTL: telomere length) adjusted for age and standardized. Survivors self-reported the presence of 10 symptom domains (cardiac, pulmonary, sensory, motor/movement, nausea, pain, fatigue, memory, anxiety, and depression) that were aggregated into a total symptom burden score. Multiple linear regression tested the association between each aging biomarker and symptom prevalence, adjusting for the age of symptom survey, sex, and cancer treatment exposures. Cox regression tested the association of each aging biomarker or symptom domain with mortality. Aging biomarkers mediation for the symptom-mortality association was assessed by using the Accelerated Failure Time model and the mediation R package. False discovery rate was controlled for multiple testing. Results: Among 2,206 survivors (47% males) who had DNAm measured on (52%) or after the survey, the median duration from the symptom survey to DNA sampling were 0.48 years (IQR: 0.09-4.27 years). EAA_GrimAge was the aging biomarker most closely associated with total symptom burden (beta [95%CI] = 0.576 [0.455, 0.697] years, P=2.89×10-18) and eight of ten domain-specific symptoms except for motor/movement and memory. Seven aging biomarkers (e.g., DNAmB2M: 1.91 [1.48, 2.48], P=1.87×10-5; EAA_GrimAge: HR [95%CI] = 1.17 [1.09, 1.26], P=3.1×10-4 ) and five symptom domains (e.g., pulmonary: 2.54 [1.44, 4.49], P=0.004; cardiac: 2.25[1.28, 3.97], P=0.01; total symptom burden: 1.47 [1.18, 1.82], P=0.0019) were associated with mortality risk. EAA (e.g., EAA_GrimAge) mediated the association between symptoms (cardiac: % mediation =0.13 [0.044, 0.379], P=0.008; pulmonary: 0.186 [0.075, 0.486], P=0.008; and total symptoms: 0.206 [0.078, 0.503], P=0.012) and late mortality. In addition, the association between symptoms and mortality was mediated by DNAmB2M and DNAmTL (e.g., pulmonary: 0.152 [0.046, 0.378], P=0.008; 0.12 [0.031, 0.373], P=0.021). Conclusions: EAA, DNAmB2M and DNAmTL mediated the association between the presence of specific symptom domains and late-mortality, suggesting that accelerated molecular aging may be an underlying biological pathway explaining the associations between symptom burden and mortality. Citation Format: Qian Li, Yue Pan, Xijun Zhang, Noel-Marie Plonski, g Chen, Qian Dong, Kyla Shelton, John Easton, Heather Mulder, Jinghui Zhang, Geoffrey Neale, Emily Walker, Deo Kumar Srivastava, Greg T. Armstrong, Kirsten Ness, I-Chan Huang, Zhaoming Wang. DNA methylation based aging biomarkers mediate the association between patient-reported symptoms and all-cause late-mortality: A report from the St. Jude Lifetime Cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6384.

Abstract 2332: Correlation of Lifestyle Factors with Epigenetic Aging Unveiled in the Practice of a DNA Methylation-Based Age Test

Abstract P2-09-02: Evidence of Accelerated Epigenetic Aging of Breast Tissues in Patients with Breast Cancer Compared to Women Without Cancer

The Sociodemographic and Lifestyle Correlates of Epigenetic Aging in a Nationally Representative U.S. Study of Younger Adults

Abstract 7010: A pan-tissue investigation of epigenetic aging in association with genetic risk for cancer among European descendants

Exploring the Relationships between Lifestyle Patterns and Epigenetic Biological Age Measures in Men

Abstract 828: Accelerated Epigenetic Aging in Bladder Cancer Patients

Epigenome-Wide Scans Identify Differentially Methylated Regions for Age and Age-Related Phenotypes in A Healthy Ageing Population

DNA methylation age of blood predicts all-cause mortality in later life

Sociodemographic and Lifestyle Factors and Epigenetic Aging in US Young Adults: NIMHD Social Epigenomics Program

Abstract P180: Relative Contributions Of Six Lifestyle Components To Epigenetic Aging In The Coronary Artery Risk Development In Young Adults (CARDIA) Study

Abstract 6384: DNA Methylation Based Aging Biomarkers Mediate the Association Between Patient-Reported Symptoms and All-Cause Late-Mortality: A Report from the St. Jude Lifetime Cohort

A High‐throughput Targeted Bisulfite Sequencing‐based Analysis for Epigenetic Age Quantification and Monitoring

A Longitudinal Study of DNA Methylation As a Potential Mediator of Age-Related Diabetes Risk

Genome-wide association studies identify 137 genetic loci for DNA methylation biomarkers of aging

Genome-wide association studies identify 137 loci for DNA methylation biomarkers of ageing

[Association of Lifestyle and Cardiometabolic Risk Factors with Epigenetic Age Acceleration in Adults in China].

Weight management intervention identifies association of decreased DNA methylation age with improved functional age measures in older adults with obesity

DNA methylation age as a biomarker for cancer

Abstract 146: DNA Methylation Age of Paired Tumor-Normal Breast Tissue in Chinese Women with Breast Cancer

DNA methylation correlates of chronological age in diverse human tissue types

An epigenetic biomarker of aging for lifespan and healthspan